Long-term efficacy and safety of adalimumab on a severe case of hidradenitis suppurativa
Ital J Dermatol Venerol
.
2021 Feb;156(1):101-102.
doi: 10.23736/S2784-8671.18.06194-1.
Epub 2018 Oct 22.
Authors
Raffaele D Caposiena Caro
1
,
Maria V Cannizzaro
2
,
Cosimo DI Raimondo
2
,
Eleonora DI Matteo
2
,
Elisabetta Botti
2
,
Piero Rossi
3
,
Luca Bianchi
2
Affiliations
1
Unit of Dermatology, Department of Systems Medicine, Tor Vergata University, Rome, Italy -
[email protected]
.
2
Unit of Dermatology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
3
Department of General Surgery, Tor Vergata University, Rome, Italy.
PMID:
30350561
DOI:
10.23736/S2784-8671.18.06194-1
No abstract available
MeSH terms
Adalimumab / adverse effects
Anti-Inflammatory Agents / adverse effects
Hidradenitis Suppurativa* / drug therapy
Humans
Severity of Illness Index
Substances
Anti-Inflammatory Agents
Adalimumab